BD Acquires Venclose to Enhance Portfolio of Chronic Venous Disease Treatments

December 2, 2021—BD (Becton, Dickinson and Company) announced it has acquired Venclose, Inc., a provider of solutions for the treatment of chronic venous insufficiency (CVI). Venclose was founded in 2014. Terms of the transaction were not disclosed.

According to BD, Venclose’s radio frequency (RF) ablation technology platform is designed for versatility, efficiency, and simplicity. BD noted that RF ablation catheters can potentially reduce postoperative pain and bruising in patients compared to alternative therapies for CVI.

BD stated that the Venclose system is compactly designed and provides two heating length sizes (2.5 cm and 10 cm) in one 6-F sized catheter. This dynamic dual heating length catheter provides multiple operational benefits to physicians. The Venclose system is currently available in the United States and areas of Europe, advised BD.

Paddy O’Brien, worldwide President of Peripheral Intervention for BD, commented in the company’s press release, “We’re committed to setting a new standard of excellence for people living with venous disease, and that starts with providing physicians with innovative technologies. Our acquisition of Venclose will enable us to offer a more robust portfolio of solutions to physicians who are treating the full range of venous conditions.”

He continued, “The Venclose RF ablation system strategically complements our category-leading portfolio of venous disease technologies and aligns with our focus on innovations that provide transformative solutions to improve outcomes for chronic disease and enable the transition into new care settings.”